Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development of Topical Gel of Methotrexate Incorporated Ethosomes and Salicylic Acid for the Treatment of Psoriasis

Author(s): Akhilesh Chandra, Geeta Aggarwal, Satish Manchanda and Akshay Narula*

Volume 7, Issue 5, 2019

Page: [362 - 374] Pages: 13

DOI: 10.2174/2211738507666190906123643

Abstract

Background: There is an unmet need for optimized drug delivery system of psoriasis therapy because of various issues like adverse reaction, permeation problem associated with convention treatment (oral and topical) available for psoriasis.

Objective: The goal was to develop an ethosomal gel of methotrexate (MTX)-incorporated ethosomes and salicylic acid (SA) and to evaluate and study its ethosomal gel potential in Imiquimod-induced psoriasis animal model to treat symptoms of psoriasis.

Methods: MTX-SA ethosomal gel was prepared by the cold method given by Touitou et al. and optimized by comparing it with MTX ethosomal gel and drug solution. Particle size, zeta potential, entrapment efficiency, and ex-vivo study were selected as the critical quality checking attributes. Psoriatic Area and Severity Index (PASI) score & histopathological examination were done for checking Antipsoriatic potential of MTX-SA ethosomal gel by using the imiquimod-induced psoriasis model.

Results: Optimized MTX-SA exhibited a particle size of 376.04 ± 3.47nm, EE(Entrapment efficiency) of 91.77 ± 0.02%. At the end of 24h, MTX-SA ethosomal gel exhibited a slow and prolonged release of MTX (26.13 ± 1.61% versus 6.97 ± 0.06%) compared to MTX drug solution. It also attributes of 43% retention study as compared to drug solution (13%). Besides, it essentially decreased the PASI score with the recuperation of normalcy of the mice's skin, while the MTX-SA gel displayed indications of gentle hyper and parakeratosis toward the completion of investigation when contrasted with the blank gel.

Conclusion: The developed MTX-SA ethosomal gel formulation can be a promising alternative to existing MTX formulation in topically treating psoriasis.

Keywords: Ethosomes, methotrexate, salicylic acid, topical therapy, topical gel, psoriasis.

« Previous Next »
Graphical Abstract

[1]
L.M. Psoriasis. Lancet 2003; 361: 1197-204.
[2]
Kivelevitch DN, Hebeler KR, Patel M, Menter A. Emerging topical treatments for psoriasis. Expert Opin Emerg Drugs 2013; 18(4): 523-32.
[3]
Laws PM, Young HS. Topical treatment of psoriasis. Expert Opin Pharmacother 2010; 11(12): 1999-2009.
[4]
Touitou E. Drug delivery across the skin. Expert Opin Biol Ther 2002; 2(7): 723-33.
[5]
Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010; 160(4): 810-20.
[6]
Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release 2007; 123(2): 148-54.
[7]
Singka GSL, Samah NA, Zulfakar MH, Yurdasiper A, Heard CM. Enhanced topical delivery and anti-inflammatory activity of methotrexate from an activated nanogel. Eur J Pharm Biopharm 2010; 76(2): 275-81.
[8]
Lee WR, Shen SC, Fang CL, Zhuo RZ, Fang JY. Topical delivery of methotrexate via skin pretreated with physical enhancement techniques: low-fluence erbium: YAG laser and electroporation. Lasers Surg Med 2008; 40(7): 468-76.
[9]
Avasatthi V, Pawar H, Dora CP, Bansod P, Gill MS, Suresh S. A novel nanogel formulation of methotrexate for topical treatment of psoriasis: optimization, in vitro and in vivo evaluation. Pharm Dev Technol 2016; 21(5): 554-62.
[10]
Ali MFM, Salah M, Rafea M, Saleh N. Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Med Sci Monit 2008; 14(12): PI66-74.
[11]
Pinto MF, Moura CC, Nunes C, Segundo MA, Costa Lima SA, Reis S. A new topical formulation for psoriasis: development of methotrexate-loaded nano-structured lipid carriers. Int J Pharm 2014; 477(1-2): 519-26.
[12]
Javadzadeh Y, Hamishehkar H. Enhancing percutaneous delivery of methotrexate using different types of surfactants. Colloids Surf B Biointerfaces 2011; 82(2): 422-6.
[13]
Kumar B, Sandhu K, Kaur I. Topical 0.25% methotrexate gel in a hydrogel base for palmoplantar psoriasis. J Dermatol 2004; 31(10): 798-801.
[14]
Mishra V, Kesharwani P, Amin MCM, Iyer A. Nanotechnology-based approaches for targeting and delivery of drugs and genes. 1st ed. Elsevier: Philadelphia 2017.
[15]
Su YH, Fang JY. Drug delivery and formulations for the topical treatment of psoriasis. Expert Opin Drug Deliv 2008; 5(2): 235-49.
[16]
Verma P, Pathak K. Therapeutic and cosmeceutical potential of ethosomes: an overview. J Adv Pharm Technol Res 2010; 1(3): 274-82.
[17]
Li G, Fan Y, Fan C, et al. Tacrolimus-loaded ethosomes: physicochemical characterization and in vivo evaluation. Eur J Pharm Biopharm 2012; 82(1): 49-57.
[18]
Parashar T. Soniya, Sachan R, et al. Ethosomes : a recent vesicle of transdermal drug delivery system. Int J Res Develop Pharm Life Sci 2013; 2(2): 285-92.
[19]
Jin-guang C, Wei L, Yu J. Preparation of curcumin ethosomes. Afr J Pharm Pharmacol 2013; 7(31): 246-2251.
[20]
Tomar S, Singhal T. Formulation and evaluation of topical gel containing azithromycin and prednisolone vesicles for treating psoriasis. Int J Pharm Res Allied Sci 2015; 4(4): 45-58.
[21]
Baboota S, Alam MS, Sharma S, Sahni JK, Kumar A, Ali J. Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis. Int J Pharm Investig 2011; 1(3): 139-47.
[22]
van der Fits L, Mourits S, Voerman JSA, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009; 182(9): 5836-45.

Rights & Permissions Print Cite
Article Metrics
36
8
© 2024 Bentham Science Publishers | Privacy Policy